All In Biotech

Drug Trial Radar · NCT03519243

Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis

Randomized Open-Label Comparative Study of the Efficacy and Safety of BCD-131 (JSC BIOCAD, Russia) and Mircera (F. Hoffmann-La Roche Ltd, Switzerland) in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis

Last checked: Nov 19, 2026Latest source record: Mar 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

75

Actual

Start

Oct 24, 2017

Primary completion

Dec 1, 2018

Study completion Dec 10, 2018

Sponsor

Lead sponsor
BiocadIndustry
Sponsor type
Industry
First posted
May 8, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

BCD-131 is pegylated darbepoetin beta. BCD-131-2 is International Multicenter Randomized Open-Label Comparative Study (Phase II) of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis.

Conditions

  • Anemia

Interventions

  • BCD-131Biological

    subcutaneously monthly

  • MirceraBiological

    subcutaneously monthly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation PeriodTime frame: Baseline - measurements on Screening (weeks -4 - 0) and on day 1; Evaluation period - weekly measures on weeks 21 to 23

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • City Clinical Hospital №9

    Minsk, Belarus

  • City Mariin Hospital

    Saint Petersburg, Russia

  • B.Braun Avitum Russland Clinics Ltd.

    Saint Petersburg, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.